1. Home
  2. CBAT vs SERA Comparison

CBAT vs SERA Comparison

Compare CBAT & SERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CBAK Energy Technology Inc.

CBAT

CBAK Energy Technology Inc.

HOLD

Current Price

$0.89

Market Cap

79.2M

Sector

Miscellaneous

ML Signal

HOLD

Logo Sera Prognostics Inc.

SERA

Sera Prognostics Inc.

HOLD

Current Price

$3.07

Market Cap

90.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CBAT
SERA
Founded
1999
2008
Country
China
United States
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Precision Instruments
Sector
Miscellaneous
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
79.2M
90.6M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
CBAT
SERA
Price
$0.89
$3.07
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
120.7K
33.2K
Earning Date
11-10-2025
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$161,757,685.00
$95,000.00
Revenue This Year
$16.06
$19.22
Revenue Next Year
$70.59
$400.00
P/E Ratio
N/A
N/A
Revenue Growth
N/A
1.06
52 Week Low
$0.57
$1.37
52 Week High
$1.28
$9.13

Technical Indicators

Market Signals
Indicator
CBAT
SERA
Relative Strength Index (RSI) 47.71 48.25
Support Level $0.86 $2.81
Resistance Level $0.91 $3.14
Average True Range (ATR) 0.03 0.26
MACD 0.00 -0.01
Stochastic Oscillator 43.42 34.67

Price Performance

Historical Comparison
CBAT
SERA

About CBAT CBAK Energy Technology Inc.

CBAK Energy Technology Inc is engaged in the manufacture, commercialization, and distribution of a variety of standard and customized lithium and sodium high-power rechargeable batteries. The batteries are used in light electric vehicles, electric vehicles, energy storage devices, and other high-power applications. The company has two operating segments: CBAK, which derives maximum revenue, and includes the manufacturing, commercialization, and distribution of various standard and customized lithium-ion rechargeable batteries; and the Hitrans segment, which includes the development and manufacturing of NCM precursor and cathode materials. Geographically, the company derives its key revenue from Mainland China, followed by Europe and other regions.

About SERA Sera Prognostics Inc.

Sera Prognostics Inc is a health diagnostic company. It develops diagnostic tests for the early prediction of a woman's individualized risk of premature birth, preeclampsia, gestational diabetes, stillbirth, and other conditions. The proprietary proteomics and bioinformatics platform of the company helps to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services. The Company operates as one operating segment, which is developing and commercializing its medical diagnostic products and services.

Share on Social Networks: